Skip to main content
. Author manuscript; available in PMC: 2017 Dec 20.
Published in final edited form as: Eur J Cancer. 2017 Jun 23;82:80–91. doi: 10.1016/j.ejca.2017.05.031

Fig. 1.

Fig. 1

Change in baseline in HRQoL for total quality-of-life population. Mean (SD) EORTC QLQ-C30 global health score (A) at baseline was 74.7 (19.4) for nivolumab, 70.7 (22.3) for nivolumab + ipilimumab, and 73.5 (20.5) for ipilimumab; mean (SD) EQ-5D utility index score (B) at baseline was 0.803 (0.219) for nivolumab, 0.779 (0.234) for nivolumab + ipilimumab, and 0.791 (0.226) for ipilimumab; mean (SD) EQ-5D VAS score (C) at baseline was 75.9 (18.5) for nivolumab, 74.0 (19.9) for nivolumab + ipilimumab, and 75.8 (18.3) for ipilimumab. Clinical significance (denoted by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30, 0.8 points for EQ-5D utility index, and 7 points for EQ-5D VAS. SD, standard deviation.